Key Insights

Highlights

Success Rate

93% trial completion (above average)

Published Results

359 trials with published results (14%)

Research Maturity

1541 completed trials (61% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.4%

112 terminated out of 2538 trials

Success Rate

93.2%

+6.7% vs benchmark

Late-Stage Pipeline

20%

512 trials in Phase 3/4

Results Transparency

23%

359 of 1541 completed with results

Key Signals

359 with results93% success112 terminated

Data Visualizations

Phase Distribution

2,127Total
Not Applicable (1185)
Early P 1 (17)
P 1 (216)
P 2 (197)
P 3 (239)
P 4 (273)

Trial Status

Completed1,541
Unknown315
Recruiting275
Not Yet Recruiting114
Terminated112
Active Not Recruiting89

Trial Success Rate

93.2%

Benchmark: 86.5%

Based on 1541 completed trials

Clinical Trials (2538)

Showing 20 of 20 trials
NCT06993792Phase 3Active Not Recruiting

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

NCT06730113Recruiting

Youth-Onset Type 2 Diabetes and Heart Disease: The Young at Heart Prospective Cohort Study

NCT07318207Not ApplicableRecruitingPrimary

Time-restricted Eating for Patients With Type 2 Diabetes

NCT06067399RecruitingPrimary

Relationship Between Red Cell Distribution Width (RDW) and HbA1C in Patients With Type 2 Diabetes Mellitus After Glycemic Control

NCT05929079Phase 3CompletedPrimary

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

NCT07736040Not ApplicableNot Yet RecruitingPrimary

The Impact of Diabetes Remission on Aging

NCT07032844Not ApplicableRecruitingPrimary

Advancing Diabetes Management for People With Physical Disabilities Optimally Through Primary Care-Based Telehealth (ADDOPT)

NCT06649344Phase 3CompletedPrimary

A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes

NCT07564414Phase 3Recruiting

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

NCT07702890Phase 1Recruiting

A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D

NCT07734259Not ApplicableNot Yet Recruiting

Voice-activated and Touchscreen-controlled Smart Speaker Intervention for Older Adults With Poorly Controlled Type 2 Diabetes

NCT07731399RecruitingPrimary

Specimen and Data Collection in South Carolina Medicaid-Enrolled Patients With Type 2 Diabetes (T2D) and Metabolically Healthy Controls

NCT07718867Not ApplicableNot Yet RecruitingPrimary

Point-of-care Capillary HbA1c Testing for Type 2 Diabetes Screening Among At-risk Individuals in Rural Dali, China

NCT07732218Phase 4CompletedPrimary

Efficacy of Once Weekly Semaglutide in Patients With Type 2 Diabetes: a Non Randomized Clinical Trial

NCT07674628Not ApplicableRecruitingPrimary

SALUD-M: Acceptance Based Coping Skills for Hispanic/Latinx Military Patients With Type 2 Diabetes

NCT07622628Not ApplicableRecruitingPrimary

AIM-MET: AI-Guided Microbiome-Targeted Nutrition for Glycemic Improvement in Type 2 Diabetes

NCT07722910Recruiting

Observation of Iris Blood Flow Via OCTA in Diabetic Neovascular Glaucoma

NCT05351359Not ApplicableCompletedPrimary

mHealth Intervention to Increase Physical Activity in Prediabetes and Type 2 Diabetes

NCT06836479Not ApplicableRecruiting

Using Continuous Glucose Monitoring to Quantify the Effects of NOURISH's Culturally Modified Meals on Asian Americans With Type 2 Diabetes

NCT07400653Phase 3Active Not Recruiting

A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

Scroll to load more

Research Network

Activity Timeline